`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`TEVA PHARMACEUTICALS USA, INC. AND WATSON
`LABORATORIES, INC.
`Petitioners,
`
`v.
`MERCK SHARP & DOHME CORP.
`Patent Owner.
`
`
`Case IPR2020-01045
`Patent 7,326,708
`
`PETITIONERS’ UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`United States Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`Case IPR2020-01045
`Patent 7,326,708
`Petitioner
`Exhibit #
`1001
`1002
`1003
`1004
`1005
`1006
`
`1007
`1008
`1009
`1010
`
`1011
`1012
`1013
`1014
`1015
`
`1016
`
`1017
`
`1018
`
`1019
`
`1020
`
`1021
`
`1022
`
`Description
`
`U.S. Patent No. 7,326,708
`Declaration of Dr. Leonard Chyall
`CV of Dr. Leonard Chyall
`WO 03/004498 to Edmonson
`Brittain, “Polymorphism in Pharmaceutical Solids”
`Bastin et al. “Salt Selection and Optimisation [sic] Procedures for
`Pharmaceutical New Chemical Entities”
`U.S. Patent No 6,699,871
`Orange Book Entry for Janumet®
`Orange Book Entry for Januvia®
`Complete copy of the prosecution history of the ’708 patent as
`available for download from the USPTO website
`U.S. Patent No. 4,572,909
`U.S. Provisional Application No. 60/303,474, filed July 6, 2001
`Prescribing Information for Janumet®
`Prescribing Information for Januvia®
`Merck Sharpe & Dohme’s Responses and Objections to
`Defendants’ First Set of Joint Interrogatories (1-10)
`Brown et al., Chemistry: The Central Science, 8th Revised Edition
`615-618 (2002)
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.,
`IPR2020-00040, Ex. 1002, Declaration of Dr. Mukund
`Chorghade, Ph.D. (Oct. 29, 2019)
`Declaration of Emily L. Rapalino in Support of Petitioners’
`Motion for Pro Hac Vice Admission of Emily L. Rapalino Under
`37 C.F.R. § 42.10(c)
`Email from Merck to Joinder Petitioners Regarding Silent
`Understudy Conditions
`Complaint, Merck Sharp & Dohme Corp. v. Dr. Reddy’s
`Laboratories, Inc. et al., No. 1:20-cv-00847-RGA, ECF 1 (D. Del.
`June 24, 2020)
`Decision, State of Israel Commissioner of Patents, Designs and
`Trademarks, Teva Pharmaceutical Industries Ltd. Opposition to
`Merck Sharp & Dohme Corp. Patent Application No. 172563
`(July 30, 2019)
`Third Declaration of Leonard J. Chyall, Ph.D.
`
`
`
`2
`
`
`
`Case IPR2020-01045
`Patent 7,326,708
`Petitioner
`Exhibit #
`1023
`
`
`
`Dated: November 24, 2020
`
`Description
`Settlement Agreements [Parties and Board Only]
`
`Respectfully submitted,
`
` /Keith A. Zullow/
`Keith A. Zullow
`(Reg. No. 37,975)
`Goodwin Procter LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018-1405
`Tel: 212-813--8800
`Fax: 212-355-3333
`kzullow@goodwinlaw.com
`
`Lead Counsel for Petitioners Teva
`Pharmaceuticals USA, Inc. and Watson
`Laboratories, Inc.
`
`
`
`
`
`
`
`
`3
`
`
`
`Case IPR2020-01045
`Patent 7,326,708
`
`CERTIFICATION OF SERVICE
`Pursuant to 37 C.F.R. §§ 42.6(e) and 42.8(b)(4), the undersigned hereby
`
`certifies that the above-captioned “PETITIONERS’ UPDATED EXHIBIT LIST”
`
`was served electronically via e-mail on November 24, 2020 on the following counsel
`
`of record:
`
`Stanley E. Fisher
`Bruce R. Genderson
`Jessamyn S. Berniker
`Alexander S. Zolan
`Elise M. Baumgarten
`Shaun P. Mahaffy
`Anthony H. Sheh
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`sfisher@wc.com
`bgenderson@wc.com
`jberniker@wc.com
`azolan@wc.com
`ebaumgarten@wc.com
`smahaffy@wc.com
`asheh@wc.com
`MerckSitagliptin@wc.com
`Dated: November 24, 2020
`
`Respectfully submitted,
`Goodwin Procter LLP
`
`/Keith A. Zullow/
`Keith A. Zullow (Reg. No. 37,975)
`Lead Counsel for Petitioners Teva
`Pharmaceuticals USA, Inc. and Watson
`Laboratories, Inc.
`
`
`
`4
`
`